Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04192344 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
A Phase 1 study of Neoplasms and Tenosynovial Giant Cell Tumor, sponsored by Abbisko Therapeutics Co.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 276
- Enrollment target
- 17
- Study locations
NCT04192344 is a Phase 1 study of Neoplasms and Tenosynovial Giant Cell Tumor that is actively recruiting participants, run by Abbisko Therapeutics Co. The registered enrollment target is 276 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (83% lower). The trial reports 17 study locations across 14 states.
The verdict
NCT04192344, a Phase 1 study of Neoplasms and Tenosynovial Giant Cell Tumor, is actively recruiting participants, sponsored by Abbisko Therapeutics Co.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 276 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
Conditions Studied
Interventions
- DRUG ABSK021
Study Locations (17)
Henan
- Henan Cancer Hospital - Zhengzhou
- The First Affiliated Hospital of Zhengzhou Universtity - Zhengzhou
Jiangsu
- Jiangsu Province Hospital - Nanjing
- Nanjing Drum Tower Hospital - Nanjing
Shanghai Municipality
- Huashan Hospital of Fudan University - Shanghai
- Shanghai Sixth People's Hospital - Shanghai
California
- Precision NextGen Oncology - Beverly Hills
Colorado
- SCRI at HealthOne - Denver
Georgia
- The Winship Cancer Institute of Emory University - Atlanta
Texas
- MD Anderson Cancer Center - Houston
Beijing Municipality
- Beijing Jishuitan Hospital - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2020-01-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04192344
The ClinicalTrials.gov registry entry for NCT04192344 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (83% lower). The listed sponsor is Abbisko Therapeutics Co, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which ABSK021 is the first listed.
NCT04192344 reports 17 study locations spanning 14 distinct geographic areas - top geographies include Henan, Jiangsu, Shanghai Municipality.
Frequently Asked Questions
What is clinical trial NCT04192344 about?
NCT04192344 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor". This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
What is the current status of trial NCT04192344?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 276 participants. The study started on 2020-01-20. Estimated completion is 2026-12-31.
What conditions does trial NCT04192344 study?
This clinical trial studies the following conditions: Neoplasms, Tenosynovial Giant Cell Tumor.
What interventions are being tested in trial NCT04192344?
The interventions under investigation include: ABSK021 (DRUG).
Who is sponsoring clinical trial NCT04192344?
This trial is sponsored by Abbisko Therapeutics Co, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04192344 being conducted?
This trial has 17 study locations across California, Colorado, Georgia, Texas, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.